Alcorn Jane, McNamara Patrick J
Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0082, USA.
Clin Pharmacokinet. 2002;41(12):959-98. doi: 10.2165/00003088-200241120-00003.
Dramatic developmental changes in the physiological and biochemical processes that govern drug pharmacokinetics and pharmacodynamics occur during the first year of life. These changes may have significant consequences for the way infants respond to and deal with drugs. The ontogenesis of systemic clearance mechanisms is probably the most critical determinant of a pharmacological response in the developing infant. In recent years, advances in molecular techniques and an increased availability of fetal and infant tissues have afforded enhanced insight into the ontogeny of clearance mechanisms. Information from these studies is reviewed to highlight the dynamic and complex nature of developmental changes in clearance mechanisms in infants during the first year of life. Hepatic and renal elimination mechanisms constitute the two principal clearance pathways of the developing infant. Drug metabolising enzyme activity is primarily responsible for the hepatic clearance of many drugs. In general, when compared with adult activity levels normalised to amount of hepatic microsomal protein, hepatic cytochrome P450-mediated metabolism and the phase II reactions of glucuronidation, glutathione conjugation and acetylation are deficient in the neonate, but sulfate conjugation is an efficient pathway at birth. Parturition triggers the dramatic development of drug metabolising enzymes, and each enzyme demonstrates an independent rate and pattern of maturation. Marked interindividual variability is associated with their developmental expression, making the ontogenesis of hepatic metabolism a highly variable process. By the first year of life, most enzymes have matured to adult activity levels. When compared with adult values, renal clearance mechanisms are compromised at birth. Dramatic increases in renal function occur in the ensuing postpartum period, and by 6 months of age glomerular filtration rate normalised to bodyweight has approached adult values. Maturation of renal tubular functions exhibits a more protracted time course of development, resulting in a glomerulotubular imbalance. This imbalance exists until adult renal tubule function values are approached by 1 year of age. The ontogeny of hepatic biliary and renal tubular transport processes and their impact on the elimination of drugs remain largely unknown. The summary of the current understanding of the ontogeny of individual pathways of hepatic and renal elimination presented in this review should serve as a basis for the continued accruement of age-specific information concerning the ontogeny of clearance mechanisms in infants. Such information can only help to improve the pharmacotherapeutic management of paediatric patients.
在生命的第一年,支配药物药代动力学和药效学的生理生化过程会发生显著的发育变化。这些变化可能会对婴儿对药物的反应和处理方式产生重大影响。全身清除机制的个体发生可能是发育中婴儿药理反应的最关键决定因素。近年来,分子技术的进步以及胎儿和婴儿组织的可获得性增加,使人们对清除机制的个体发生有了更深入的了解。本文回顾了这些研究的信息,以突出婴儿生命第一年清除机制发育变化的动态和复杂性。肝脏和肾脏清除机制是发育中婴儿的两个主要清除途径。药物代谢酶活性主要负责许多药物的肝脏清除。一般来说,与以肝微粒体蛋白量标准化的成人活性水平相比,新生儿肝脏细胞色素P450介导的代谢以及葡萄糖醛酸化、谷胱甘肽结合和乙酰化的II相反应不足,但硫酸结合在出生时是一种有效的途径。分娩触发了药物代谢酶的显著发育,每种酶都表现出独立的成熟速率和模式。其发育表达存在明显的个体间差异,使得肝脏代谢的个体发生成为一个高度可变的过程。到生命的第一年,大多数酶已成熟到成人活性水平。与成人值相比,出生时肾脏清除机制受损。产后随后时期肾功能急剧增加,到6个月大时,以体重标准化的肾小球滤过率已接近成人值。肾小管功能的成熟表现出更长的发育时间进程,导致肾小球肾小管失衡。这种失衡一直存在,直到1岁时接近成人肾小管功能值。肝脏胆汁和肾小管转运过程的个体发生及其对药物消除的影响在很大程度上仍然未知。本综述中对肝脏和肾脏清除各个途径个体发生的当前理解总结,应作为持续积累有关婴儿清除机制个体发生的年龄特异性信息的基础。此类信息只会有助于改善儿科患者的药物治疗管理。